Less Anti‐infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators

Abstract

In children with CD combination therapy is associated with significant reduction of antibody formation and prolonged effectivity compared to IFX monotherapy. ECI for at least 12 months, followed by IFX monotherapy, may be an equally effective alternative to CCI.